BRCA1 Antibody - #AF6289

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(4)   (5)  
产品: BRCA1 抗体
货号: AF6289
描述: Rabbit polyclonal antibody to BRCA1
应用: WB IHC IF/ICC
文献验证: WB
反应: Human
预测: Pig
蛋白号: P38398
RRID: AB_2835139

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human
克隆:
Polyclonal
特异性:
BRCA1 Antibody detects endogenous levels of total BRCA1.
RRID:
AB_2835139
引用格式: Affinity Biosciences Cat# AF6289, RRID:AB_2835139.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

BRCA 1; BRCA1; BRCA1 DNA repair associated; BRCA1/BRCA2 containing complex subunit 1; BRCA1/BRCA2-containing complex, subunit 1; BRCA1_HUMAN; BRCAI; BRCC 1; BRCC1; Breast and ovarian cancer susceptibility protein 1; Breast Cancer 1; Breast Cancer 1 Early Onset; Breast cancer type 1 susceptibility protein; BROVCA1; FANCS; IRIS; PNCA4; PPP1R53; Protein phosphatase 1 regulatory subunit 53; PSCP; RING finger protein 53; RNF53;

抗原和靶标

免疫原:

A synthesized peptide derived from human BRCA1, corresponding to a region within the internal amino acids.

基因/基因ID:
BRCA1(672)
描述:
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as BASC for BRCA1-associated genome surveillance complex.

研究领域

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Genetic Information Processing > Replication and repair > Homologous recombination.

· Genetic Information Processing > Replication and repair > Fanconi anemia pathway.

· Genetic Information Processing > Folding, sorting and degradation > Ubiquitin mediated proteolysis.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

文献引用

1). 4-Hydroxynonenal Promotes Colorectal Cancer Progression Through Regulating Cancer Stem Cell Fate. Antioxidants & redox signaling, 2025 (PubMed: 39264845) [IF=5.9]
2). PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway. Frontiers in cell and developmental biology, 2021 (PubMed: 34497808) [IF=4.6]

Application: WB    Species: Human    Sample:

FIGURE 6. Treatment of Oxaliplatin inhibits HR repair pathways via blocking CDK1-BRCA1 activities in Oxaliplatin resistance cell line. (A) Verification by WB on the effects of Olaparib + Oxaliplatin, Oxaliplatin, Olaparib, AG-02432 and cisplatin on CDK1 expression and its phosphorylation, BRCA1 expression and its phosphorylation, RAD51 expression in SNU719, MKN74, and AGS Oxaliplatin resistance strains. Drug action time was 36 h. (B) Histochemical results of protein phosphorylation in gastric cancer patients. (C,D) The effects of Olaparib + Oxaliplatin and cisplatin combined with CDK1 inhibitor Olaparib on colony formation of overexpressed PARP1 and normally expressed PARP1 cell lines in SNU719, MKN74, and AGS Oxaliplatin resistance strains. Colonies were stained with crystal violet. The Student’s t test was used for statistical analysis. Error bars indicate mean ± standard deviation. OXA, Oxaliplatin. OLP, Olaparib. CON, control group. CISP, cisplatin. PCDK1, CDK1 phosphorylation antibody. PBRCA1, BRCA1 phosphorylation antibody. AGSR, AGS Oxaliplatin resistance. SNU719R, SNU719 Oxaliplatin resistance. MKN74R, MKN74 Oxaliplatin resistance. ∗< 0.05. All experiments were repeated three times.
3). Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1. MOLECULAR CANCER RESEARCH, 2020 (PubMed: 31722968) [IF=4.1]

Application: WB    Species: human    Sample: ovarian

Fig. 3. |PARP1 promotes DNA DSB repair in ovarian cancer.D and E, Expression of PARP1, BRCA1, and Rad51 in conditions where shPARP1 or PARP1 cDNA were transfected. Three experiments were done.
4). Anticancer Effect of Puerarin on Ovarian Cancer Progression Contributes to the Tumor Suppressor Gene Expression and Gut Microbiota Modulation. Journal of Immunology Research, 2022 (PubMed: 35935578) [IF=3.5]

Application: WB    Species: Rat    Sample: tumor tissues

Figure 5 Expression of cell proliferation and tumor suppressor genes was regulated by puerarin treatment in OC model rats. (a) Positive expression of Ki67, PCNA, P53, and PTEN in tumor tissues was detected by an immunohistochemistry assay (magnification: ×200). (b) Protein expression levels of P53, P21, PTEN, BRCA1, BIRC5, and CTGF in tumor tissues were detected by Western blot assay, and GAPDH was used as the internal control. OC: ovarian cancer.

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.